Advanced search
Publication Cover
Renal Failure Volume 45, 2023 - Issue 1
Submit an article Journal homepage
858
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

A case of pazopanib-induced acute kidney injury, reversible hair depigmentation and radiation recall dermatitis

Jun Lia Department of Geriatric Medicine, Peking University First Hospital, Beijing, ChinaView further author information
,
Zhiying Lib Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China;c Institute of Nephrology, Peking University, Beijing, ChinaView further author information
&
Tao Sub Renal Division, Department of Medicine, Peking University First Hospital, Beijing, China;c Institute of Nephrology, Peking University, Beijing, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6857-8146View further author information
ORCID Icon
Article: 2213778 | Received 15 Feb 2023, Accepted 09 May 2023, Published online: 02 Jun 2023

References

  • Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 2007;9(2):1–3.
  • Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer. 2013;49(6):1287–1296.
  • Suttle AB, Ball HA, Molimard M, et al. Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer. 2014;111(10):1909–1916.
  • Küronya Z, Szőnyi MD, Nagyiványi K, et al. Predictive markers of first line pazopanib treatment in kidney cancer. Pathol Oncol Res. 2020;26(4):2475–2481.
  • Erman M, Biswas B, Danchaivijitr P, et al. Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in asia pacific, North africa, and Middle east regions: PARACHUTE study. Bmc Cancer. 2021;21(1):1021.
  • Tobin DJ. Human hair pigmentation–biological aspects. Int J Cosmet Sci. 2008;30(4):233–257.
  • Gu X, Zhang S, Zhang T. Abnormal crosstalk between endothelial cells and podocytes mediates tyrosine kinase inhibitor (TKI)-induced nephrotoxicity. CELLS-BASEL. 2021;10(4):869.
  • Land JD, Chen AH, Atkinson BJ, et al. Proteinuria with first-line therapy of metastatic renal cell cancer. J Oncol Pharm Pract. 2016;22(2):235–241.
  • Maruyama K, Nakagawa N, Suzuki A, et al. Pazopanib-induced endothelial injury with podocyte changes. Intern Med. 2018;57(7):987–991.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.